Assessing Closed-loop Insulin Delivery in Children With Type 1 Diabetes.

McGill University10 enrolled

Overview

The objective of this clinical trial is to assess the safety of our insulin dosing algorithm in children with type 1 diabetes in a free-living study.

This is a preliminary pilot study to generate data to optimize an insulin dosing algorithm to regulate glucose levels in children with type 1 diabetes. There will be up to two 40-hour test in outpatient settings, in which we will assess an insulin dosing algorithm. The two tests will allow us to compare different tunings in the same patient (this allows easier interpretation of the data). For example, if in a specific participant, the dosing algorithm reduced insulin delivery at night to avoid low blood glucose levesl but led to a rebound increase in glucose levels, then a second visit with a slightly different target range will help answer this question. The objective of this clinical trial is to assess the safety of our algorithm in children with type 1 diabetes in a free-living study.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Diabetes Mellitus, Type 1

Interventions

Insulin-alone closed-loopOTHER

40-hour intervention period using the insulin-alone closed-loop system.

Eligibility

Sex: ALLMin age: 2 YearsMax age: 13 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Male or female children between 2 and 13 years of age. 2. Clinical diagnosis of type 1 diabetes mellitus (the diagnosis of type 1 diabetes is based on the investigator's judgment). 3. Using insulin pump therapy for at least 3 months 4. For participants aged 7-13 years: Total daily insulin dose ≤ 40 units and 0.5 ≥ units/kg/day. For participants aged 2-6 years: Total daily insulin dose \[8, 40\] units and 0.3 ≥ units/kg/day. 5. Most recent (in the last 6 months) HbA1c ≤ 12%. Exclusion Criteria: 1. Using Medtronic 670G automated insulin delivery system (since participant's basal rates and insulin-to-carbohydrate ratios may reflect the use of 670G; generally overestimated by 20%). 2. Severe hypoglycaemia or ketoacidosis episode ≤ two months before admission. 3. Medical illness or other issues likely to interfere with study participation or with the ability to complete the trial by the judgment of the investigator.

Locations (1)

McGill University Health Centre Research Institute

Montreal, Quebec, Canada